Microba’s commitment to developing life-changing therapeutics derived from the gut microbiome will add a valuable voice to MTIG’s mission.
We are innovating to help humanity achieve some of its most inspiring medical advancements in the 21st century. Read about Microba’s progress, partnership news and latest discoveries.
The partnership's first clinical trial will determine if a new treatment can restore beneficial gut microbiome species and improve symptoms.
Bringing Microba’s world-leading metagenomic sequencing and bioinformatics together with Holobiome’s promising microbiome therapeutic pipeline.
Microba have partnered with Europe’s largest pathology provider, SYNLAB, to deliver leading gut microbiome analysis into Europe.
Research study at Curtin University examining possible links between infant gut microbiome composition and the development of allergies.
Microba have partnered with US company Psomagen to deliver gut microbiome analysis technology to the US market.
Microba have partnered with the Microbiome Research Centre (MRC) to power new gut microbiome research.
Improved therapies for the long-term management of IBD are crucial and a currently unmet clinical need.
Microba will join forces with other internationally-renowned research entities on a groundbreaking project to tackle antimicrobial resistance.